IBA (Ion Beam Applications S.A.), announced the start of the installation of a Cyclone® 30 XP in Poland, making a total of three sites of IBA to produce Astatine-211 (At-211) for oncology applications, establishing IBA’s commitment and strong role in the area of radiotheranostics.

The completion of the rigging in POLATOM on December 11th follows the successful commissioning of the first Cyclone®30 XP machine in Jülich, Germany, earlier last year. Furthermore, an IBA cyclotron Cyclone®70 XP, installed in France in 2008, has enabled multiple research programs already.

IBA and the three sites, ARRONAX (France), Forschungszentrum Jülich (Germany), and POLATOM (Poland), are active participants in COST Action 19114: A European Network Dedicated to Targeted Alpha Therapy (TAT) with At-211. This collaborative effort showcases a commitment to overcoming challenges and advancing targeted alpha therapy research.

To read more please visit:

IBA pioneers theranostic advancements, empowering the market to produce Astatine-211

Source: IBA